Renantos Pharmavertriebsgesellschaft

Renantos Pharmavertriebsgesellschaft mbH is a German pharmaceutical company based in Ulm, specializing in the development, registration, and distribution of pharmaceutical products. The company operates in close association with Kappler Pharma Consult GmbH, leveraging deep expertise in regulatory affairs to bring both generic and niche therapeutics to the European market. Renantos' commercial portfolio includes several widely used generic small molecules, such as Allopurinol Renantos, Esomeprazole Renantos, Telmisartan Renantos, and Olanzapine Renantos. In addition to its generic distribution business, the company is actively developing a proprietary formulation of sodium phenylbutyrate for the treatment of Maple Syrup Urine Disease (MSUD), which was granted Orphan Drug Designation by the European Medicines Agency (EMA) in 2022.